Neurohormonal Activation in Populations Susceptible to Heart Failure

Heart Failure Clinics

Volumn 1, Issue 1, 2005, Pages 11-23

  Ärnlöv, Johan ^a,b   Vasan, Ramachandran S ^a,c  

^a FRAMINGHAM HEART STUDY   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CATECHOLAMINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; NATRIURETIC FACTOR; RAMIPRIL; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE PREDISPOSITION; ETHNOLOGY; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE ACTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CATECHOLAMINES; ENDOTHELINS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646185897     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2004.11.003     Document Type: Review

References (140)

1. Harris P. Evolution and the cardiac patient. Cardiovasc Res 17 8 (1983) 437-445
2. Sigurdsson A., and Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J 132 1 Pt 2 Suppl (1996) 229-234
3. Dzau V.J., Bernstein K., Celermajer D., et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88 9A (2001) 1L-20L
4. Esler M. The sympathetic system and hypertension. Am J Hypertens 13 6 Pt 2 (2000) 99S-105S
5. O'Shaughnessy K.M., and Karet F.E. Salt handling and hypertension. J Clin Invest 113 8 (2004) 1075-1081
6. Walker W.G., Whelton P.K., Saito H., et al. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1 3 (1979) 287-291
7. Alderman M.H., Sealey J.E., and Laragh J.H. Plasma renin activity and ischemic heart disease. N Engl J Med 330 7 (1994) 506-507
8. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 19 (1998) 1921-1929
9. Schunkert H., Hense H.W., Muscholl M., et al. Association of angiotensin converting enzyme activity and arterial blood pressure in a population-based sample. J Hypertens 14 5 (1996) 571-575
10. Forrester T., McFarlane-Anderson N., Bennett F.I., et al. The angiotensin converting enzyme and blood pressure in Jamaicans. Am J Hypertens 10 5 Pt 1 (1997) 519-524
11. Tolagen K., and Karlberg B.E. Angiotensin II in primary hypertension, relationship to plasma renin activity, aldosterone and urinary electrolytes. Acta Med Scand 205 7 (1979) 557-562
12. Walker W.G., Horvath J.S., Moore M.A., et al. Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure in mild untreated hypertension. Circ Res 38 6 (1976) 470-476
13. Harrap S.B., Dominiczak A.F., Fraser R., et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 93 6 (1996) 1148-1154
14. Ljungman S., Aurell M., Hartford M., et al. Blood pressure in relation to the renin-angiotensin-aldosterone system. Acta Med Scand 211 5 (1982) 351-360
15. Genest J., Nowaczynski W., Boucher R., et al. Aldosterone and renin in essential hypertension. Can Med Assoc J 113 5 (1975) 421-431
16. Wisenbaugh P.E., Garst J.B., Hull C., et al. Renin, aldosterone, sodium and hypertension. Am J Med 52 2 (1972) 175-186
17. Tolagen K. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects. Scand J Clin Lab Invest 38 5 (1978) 487-493
18. El Gharbawy A.H., Nadig V.S., Kotchen J.M., et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37 3 (2001) 845-850
19. Vaughan Jr. E.D. Diseases of the adrenal gland. Med Clin North Am 88 2 (2004) 443-466
20. Lohmeier T.E. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 14 6 Pt 2 (2001) 147S-154S
21. Goldstein D.S. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5 1 (1983) 86-99
22. Touyz R.M., and Schiffrin E.L. Role of endothelin in human hypertension. Can J Physiol Pharmacol 81 6 (2003) 533-541
23. Saito Y., Nakao K., Mukoyama M., et al. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 322 3 (1990) 205
24. Elijovich F., Laffer C.L., Amador E., et al. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 103 2 (2001) 263-268
25. Kohno M., Yasunari K., Murakawa K., et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 88 6 (1990) 614-618
26. Shichiri M., Hirata Y., Ando K., et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 15 5 (1990) 493-496
27. Schiffrin E.L., and Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 4 4 Pt 1 (1991) 303-308
28. Ergul S., Parish D.C., Puett D., et al. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28 4 (1996) 652-655
29. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 36 1 (2000) 62-67
30. Cardillo C., Kilcoyne C.M., Waclawiw M., et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33 2 (1999) 753-758
31. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 5 (1998) 321-328
32. Buckley M.G., Markandu N.D., Miller M.A., et al. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens 7 3 (1993) 245-250
33. Kario K., Nishikimi T., Yoshihara F., et al. Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. J Hypertens 16 9 (1998) 1253-1259
34. Kato J., Kitamura K., Uemura T., et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 25 6 (2002) 887-892
35. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 92 1 (1992) 29-34
36. Talartschik J., Eisenhauer T., Schrader J., et al. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens 3 1 (1990) 45-47
37. Zachariah P.K., Burnett Jr. J.C., Ritter S.G., et al. Atrial natriuretic peptide in human essential hypertension. Mayo Clin Proc 62 9 (1987) 782-786
38. Flickinger A.L., Burnett Jr. J.C., and Turner S.T. Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc 70 10 (1995) 932-938
39. Nilsson P., Lindholm L., Schersten B., et al. Atrial natriuretic peptide and blood pressure in a geographically defined population. Lancet 2 8564 (1987) 883-885
40. Nishikimi T., Yoshihara F., Morimoto A., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28 1 (1996) 22-30
41. Vasan R.S., Evans J.C., Larson M.G., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 1 (2004) 33-41
42. Freitag M.H., Larson M.G., Levy D., et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 41 4 (2003) 978-983
43. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 3 (1997) 212-216
44. Dahlof B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338 8778 (1991) 1281-1285
45. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 9080 (1997) 757-764
46. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
47. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 15 (2000) 1967-1975
48. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
49. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 7 (2003) 583-592
50. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 9192 (1999) 1751-1756
51. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 9426 (2004) 2049-2051
52. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 9153 (1999) 611-616
53. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 9227 (2000) 359-365
54. Krum H., Viskoper R.J., Lacourciere Y., et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338 12 (1998) 784-790
55. Uemasu J., Munemura C., Fujihara M., et al. Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin Nephrol 41 3 (1994) 150-152
56. Suzuki M., Yamamoto K., Watanabe S., et al. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 108 8 (2000) 627-633
57. Schunkert H., Orzechowski H.D., Bocker W., et al. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. J Mol Med 77 8 (1999) 623-630
58. Kaddoura S., Firth J.D., Boheler K.R., et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93 11 (1996) 2068-2079
59. Schunkert H., Hense H.W., Muscholl M., et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 77 1 (1997) 24-31
60. Vasan R.S., Evans J.C., Benjamin E.J., et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43 5 (2004) 957-962
61. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction-the Framingham Heart Study. JAMA 288 10 (2002) 222-228
62. Arnlov J., Lind L., Stridsberg M., et al. N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males. J Intern Med 247 6 (2000) 699-708
63. Schirmer H., and Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study. Eur Heart J 20 10 (1999) 755-763
64. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 6 (1996) 988-994
65. Diez J., Gonzalez A., Lopez B., et al. Effects of antihypertensive agents on the left ventricle: clinical implications. Am J Cardiovasc Drugs 1 4 (2001) 263-279
66. Anan F., Takahashi N., Ooie T., et al. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53 6 (2004) 777-781
67. Kohno M., Minami M., Kano H., et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy. Metabolism 49 10 (2000) 1356-1360
68. Yalcin F., Aksoy F.G., Muderrisoglu H., et al. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clin Cardiol 23 6 (2000) 437-441
69. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
70. Petersen C.L., Nielsen J.R., Petersen B.L., et al. Catecholaminergic activation in acute myocardial infarction: time course and relation to left ventricular performance. Cardiology 100 1 (2003) 23-28
71. Rouleau J.L., de Champlain J., Klein M., et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22 2 (1993) 390-398
72. Omland T., Aarsland T., Aakvaag A., et al. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 72 3 (1993) 255-259
73. McAlpine H.M., Morton J.J., Leckie B., et al. Neuroendocrine activation after acute myocardial infarction. Br Heart J 60 2 (1988) 117-124
74. Remes J. Neuroendocrine activation after myocardial infarction. Br Heart J 72 3 Suppl (1994) S65-S69
75. Sigurdsson A., Held P., and Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126 5 (1993) 1068-1076
76. Petersen C.L., Munch M., Frandsen E., et al. Serial changes in atrial natriuretic peptide and endothelin-1 concentrations. Their relationships to the cardiac performance of patients hospitalized for acute myocardial infarction. Cardiology 89 3 (1998) 210-215
77. Rouleau J.L., Moye L.A., de Champlain J., et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 68 14 (1991) 80D-86D
78. Vantrimpont P., Rouleau J.L., Ciampi A., et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19 10 (1998) 1552-1563
79. Rouleau J.L., de Champlain J., Klein M., et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22 2 (1993) 390-398
80. Ray S.G., Morton J.J., and Dargie H.J. Relationship of renin, angiotensin II and atrial natriuretic factor to clinical status in the early post-infarct period in patients with left ventricular dysfunction. Eur Heart J 15 6 (1994) 793-800
81. Wei C.M., Lerman A., Rodeheffer R.J., et al. Endothelin in human congestive heart failure. Circulation 89 4 (1994) 1580-1586
82. Otterstad J.E., John Sutton M.G., Froeland G.S., et al. Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Eur Heart J 23 13 (2002) 1011-1020
83. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 5 (1990) 1724-1729
84. Fontana F., Bernardi P., Spagnolo N., et al. Plasma atrial natriuretic factor in patients with acute myocardial infarction. Eur Heart J 11 9 (1990) 779-787
85. Rouleau J.L., de Champlain J., Klein M., et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22 2 (1993) 390-398
86. Vaughan D.E., Lamas G.A., and Pfeffer M.A. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 66 5 (1990) 529-532
87. Wieczorek I., Haynes W.G., Webb D.J., et al. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 72 5 (1994) 436-441
88. White M., Rouleau J.L., Hall C., et al. Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 142 6 (2001) 1056-1064
89. Rouleau J.L., de Champlain J., Klein M., et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22 2 (1993) 390-398
90. Bellone P., Derchi G., Tommasini G., et al. Selective activation of atrial natriuretic peptide in patients with myocardial infarction and mild left ventricular dysfunction. Int J Cardiol 42 2 (1993) 115-120
91. Svanegaard J., Angelo-Nielsen K., and Pindborg T. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction. Br Heart J 68 1 (1992) 38-42
92. Foy S.G., Crozier I.G., Richards A.M., et al. Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Eur Heart J 16 6 (1995) 770-778
93. Benedict C.R., Johnstone D.E., Weiner D.H., et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 23 6 (1994) 1410-1420
94. Rouleau J.L., Packer M., Moye L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24 3 (1994) 583-591
95. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20 24 (1999) 1799-1807
96. Benedict C.R., Shelton B., Johnstone D.E., et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 94 4 (1996) 690-697
97. Omland T., Lie R.T., Aakvaag A., et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89 4 (1994) 1573-1579
98. Omland T., Bonarjee V.V., Lie R.T., et al. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 76 4 (1995) 230-235
99. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 14 (2001) 1014-1021
100. Arakawa N., Nakamura M., Aoki H., et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 27 7 (1996) 1656-1661
101. Hall C., Rouleau J.L., Moye L., et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 89 5 (1994) 1934-1942
102. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 22 (2003) 2786-2792
103. Sigurdsson A., Eriksson S.V., Hall C., et al. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. Eur J Heart Fail 3 1 (2001) 69-78
104. Omland T., Aarsland T., Aakvaag A., et al. The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. Int J Cardiol 42 1 (1993) 37-45
105. Gonzalez-Fernandez R.A., Altieri P.I., Lugo J.E., et al. Effects of enalapril on ventricular volumes and neurohumoral status after inferior wall myocardial infarction. Am J Med Sci 305 4 (1993) 216-221
106. Sigurdsson A., Held P., Swedberg K., et al. Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. Eur Heart J 14 8 (1993) 1110-1117
107. Benedict C.R., Francis G.S., Shelton B., et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 75 16 (1995) 1151-1157
108. Galatius-Jensen S., Wroblewski H., Emmeluth C., et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 32 6 (1996) 1148-1154
109. Maki N., Yoshiyama M., Omura T., et al. Effect of diltiazem on cardiac function assessed by echocardiography and neurohumoral factors after reperfused myocardial infarction without congestive heart failure. Cardiovasc Drugs Ther 15 6 (2001) 493-499
110. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 327 10 (1992) 685-691
111. Jong P., Yusuf S., Rousseau M.F., et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361 9372 (2003) 1843-1848
112. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
113. Vantrimpont P., Rouleau J.L., Wun C.C., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 29 2 (1997) 229-236
114. Exner D.V., Dries D.L., Waclawiw M.A., et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33 4 (1999) 916-923
115. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
116. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 9386 (2003) 782-788
117. Ambrosioni E., Borghi C., and Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332 2 (1995) 80-85
118. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 25 (1995) 1670-1676
119. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 97 22 (1998) 2202-2212
120. Aronow W.S., Ahn C., and Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 88 11 (2001) 1298-1300
121. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
122. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 9335 (2002) 752-760
123. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 17 (2002) 2144-2150
124. Hundley W.G., Kitzman D.W., Morgan T.M., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38 3 (2001) 796-802
125. Carstensen E., Ramaiya K., Denver E., et al. The contribution of the sympathoadrenomedullary system to the etiology of essential hypertension: a study using plasma and platelet catecholamine concentrations. J Clin Endocrinol Metab 80 2 (1995) 455-460
126. Jacobs M.C., Lenders J.W., Willemsen J.J., et al. Adrenomedullary secretion of epinephrine is increased in mild essential hypertension. Hypertension 29 6 (1997) 1303-1308
127. Beilin L.J., Vandongen R., Arkwright P.D., et al. Adrenal and sympathetic nervous activity in subjects with "low" and "high" normal blood pressure. J Hypertens 1 1 (1983) 13-18
128. Muscholl M.W., Schunkert H., Muders F., et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 135 1 (1998) 58-66
129. Malmqvist K., Ohman K.P., Lind L., et al. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 252 5 (2002) 430-439
130. Schlaich M.P., Klingbeil A., Hilgers K., et al. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am Heart J 138 5 Pt 1 (1999) 810-817
131. Schlaich M.P., Schobel H.P., Hilgers K., et al. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 85 10 (2000) 1199-1206
132. du Cailar G., Pasquie J.L., Ribstein J., et al. Left ventricular adaptation to hypertension and plasma renin activity. J Hum Hypertens 14 3 (2000) 181-188
133. Reneland R., Andren B., Lind L., et al. Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men. J Hypertens 15 8 (1997) 885-890
134. Schmieder R.E., Messerli F.H., Garavaglia G.E., et al. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?. Am J Med 84 3A (1988) 136-139
135. Schroeder A.P., Sihm I., Morn B., et al. Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Am J Hypertens 9 3 (1996) 207-215
136. Corea L., Bentivoglio M., Verdecchia P., et al. Plasma norepinephrine and left ventricular hypertrophy in systemic hypertension. Am J Cardiol 53 9 (1984) 1299-1303
137. Corea L., Bentivoglio M., and Verdecchia P. Echocardiographic left ventricular hypertrophy as related to arterial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment. Hypertension 5 6 (1983) 837-843
138. Olsen M.H., Wachtell K., Hermann K.L., et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J 144 3 (2002) 530-537
139. Hua L., Li C., Xia D., et al. Relationship between hypertensive left ventricular hypertrophy and levels of endothelin and nitric oxide. Hypertens Res 23 4 (2000) 377-380
140. Sayama H., Nakamura Y., Saito N., et al. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects. Gerontology 46 2 (2000) 71-77